Buy Phosphogliv lyophilisate for the preparation of intravenous solution 2.5 g No. 5 in pharmacies

How does Phosphogliv work?

Phosphogliv is considered the only drug in the country that is capable of restoring and treating one of the most important human organs - the liver.

The drug can be taken not only for existing liver diseases, but also for preventive purposes. The liver is regularly subjected to heavy loads: unhealthy food, alcoholic drinks, stressful situations, lack of an active lifestyle. All this together affects the functioning of the human body.

When taking the medicine orally, it is well absorbed in the intestines. The maximum content of the active substance in the blood plasma occurs after 8-22 hours. Excreted in urine and bile.

When administered intravenously, the drug immediately appears in the blood, and the maximum concentration occurs much faster. It is also excreted in urine and bile.

Buy Phosphogliv lyophilisate for the preparation of intravenous solution 2.5 g No. 5 in pharmacies

Trade name of the drug:

Phosphogliv®

INN or group name:

Glycyrrhizic acid+Phospholipids

Dosage form:

lyophilisate for the preparation of solution for intravenous administration

Composition per bottle

Active substances: Phospholipids (Lipoid C 100) - 0.50 g (in terms of 100% substance); Trisodium salt of glycyrrhizic acid - 0.20 g (sodium glycyrrhizinate) Excipient: Maltose - 1.80 g

Description:

lyophilized mass from white to light yellow.

Pharmacotherapeutic group:

hepatoprotective agent

Pharmacological properties

Pharmacodynamics

Combined remedy. It has membrane-stabilizing, hepatoprotective and antiviral effects.

Phosphatidylcholine (the main component of phospholipids) is the main structural element of cellular and intracellular membranes, capable of restoring their structure and function when damaged, providing a cytoprotective effect. Normalizes protein and lipid metabolism, prevents the loss of enzymes and other active substances by hepatocytes, restores liver function, inhibits the formation of connective tissue, reducing the risk of fibrosis and cirrhosis of the liver.

Glycyrrhizic acid has an anti-inflammatory effect, suppresses the reproduction of viruses in the liver and other organs by stimulating the production of interferons, increasing phagocytosis, and increasing the activity of natural killer cells. It has a hepatoprotective effect due to its antioxidant and membrane-stabilizing activity. Glycyrrhizic acid potentiates the effect of endogenous glucocorticosteroids, providing anti-inflammatory and antiallergic effects in non-infectious liver lesions.

In case of skin lesions, due to the membrane-stabilizing and anti-inflammatory effects of the components, it limits the spread of the process and promotes regression of the disease.

Pharmacokinetics

Phosphatidylcholine

By binding mainly to high-density lipoproteins, phosphatidylcholine enters, in particular, liver cells. The half-life of the choline component is 66 hours, and that of the unsaturated fatty acids is 32 hours.

Glycyrrhizic acid

Glycyrrhizic acid, entering the systemic circulation, binds to albumin and is transported to the liver. Glycyrrhizic acid is excreted unchanged in bile and in residual amounts in urine. When entering the intestine, part of it, under the influence of β-glucuronidase from intestinal microflora, is hydrolyzed into β-glycyrrhetic acid, which is reabsorbed, thereby causing enterohepatic circulation.

According to experimental data, the inclusion of glycyrrhizic acid in phospholipid nanoparticles improves its pharmacokinetic and pharmacodynamic properties, prolongs circulation in the blood and increases delivery to the liver.

Indications for use

— Fatty liver degeneration (hepatosis), alcoholic, toxic, including medicinal, liver damage. — As part of complex therapy for viral hepatitis (acute and chronic), liver cirrhosis and psoriasis.

Contraindications

Hypersensitivity to the components of the drug, antiphospholipid syndrome, pregnancy, breastfeeding, children under 12 years of age.

Use during pregnancy and breastfeeding

Due to insufficient data on effectiveness and safety, the use of the drug during pregnancy and breastfeeding is contraindicated.

Directions for use and doses

Adults and children over 12 years old. Intravenously, after dissolving the powder in 10 ml of water for injection. Intravenous administration should be carried out slowly. Administer 10 ml daily 2 times a day in the morning and evening for 10 days, followed by switching to oral administration of the drug in capsule form. The duration of the course can be increased on the recommendation of a doctor.

Side effect

A skin rash may appear (with increased individual sensitivity), which disappears after discontinuation of the drug.

If daily doses are exceeded, sodium and fluid retention, edema, increased blood pressure, and hypokalemia may occur (see section “Overdose”).

Overdose

If daily doses are exceeded, sodium and fluid retention, edema, increased blood pressure, and hypokalemia may occur. If these symptoms appear, depending on their severity, it is necessary to reduce the dose of the drug and/or prescribe spironolactone 50-100 mg per day.

There have been no cases of overdose with the administration of Phosphogliv®.

Interaction with other drugs

Glycyrrhizic acid, which is part of the drug, is a synergist of corticosteroid hormones; it enhances and prolongs their effect.

special instructions

The contents of the bottle must not be mixed with other solutions. For dissolution, use only water for injection. Do not use physiological sodium chloride solution or glucose solution to dilute the drug. Administer only intravenously.

Impact on the ability to drive vehicles and machinery

There is no data on the negative impact of the drug Phosphogliv® on driving vehicles and engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Release form

Lyophilisate for preparing a solution for intravenous administration.

2.5 g of the drug in light-protective glass bottles, hermetically sealed with stoppers for freeze-drying, rolled with aluminum caps with a plastic component or sealed with combined caps.

5 bottles of the drug, complete with 5 ampoules (bottles) of water for injection, 10 ml each, are placed in a blister pack.

One contour blister pack is placed in a cardboard pack.

Or 5 or 10 bottles of the drug with instructions for use are placed in a cardboard pack.

Storage conditions

In a place protected from light at a temperature not exceeding 25 ° C. Keep out of the reach of children.

Best before date

2 years. Do not use after the expiration date stated on the package.

Vacation conditions

Dispensed by prescription.

special instructions

The shelf life of capsules is 36 months, ampoules – 24 months from the date of production.

The drug should be kept in a dry place, out of reach of children and away from sunlight. The temperature should not exceed 20 degrees.

People with arterial or portal hypertension should take it with special caution. If your blood pressure increases after using the medicine, you should immediately stop treatment and inform your doctor.

The product in the form of an injection solution is strictly prohibited from being combined with other drugs for intravenous administration.

Phosphogliv Urso

Take orally. Children over 12 years of age and adults weighing more than 47 kg swallow the capsule whole. The drug must be taken regularly.

For convenience, dosage regimens for different indications are presented in terms of ursodeoxycholic acid.

Non-alcoholic steatohepatitis:

The average daily dose is 10-15 mg/kg in 2-3 doses. The duration of therapy ranges from 6-12 months or more.

Alcoholic liver disease:

The average daily dose is 10-15 mg/kg in 2-3 doses. The duration of therapy ranges from 6-12 months or more.

Symptomatic treatment of chronic hepatitis of various origins:

The average daily dose is 10-15 mg/kg in 2-3 doses. Duration of therapy is 6-12 months or more.

Biliary reflux gastritis:

1 capsule of the drug daily in the evening before bed. The course of treatment is from 10-14 days to 6 months, if necessary - up to 2 years.

Biliary dyskinesia:

The average daily dose is 10 mg/kg in 2 divided doses for 2 weeks to 2 months. If necessary, it is recommended to repeat the course of treatment.

Dissolution of cholesterol gallstones:

The average daily dose of ursodeoxycholic acid is 10 mg/kg per day, which corresponds to:

The drug must be taken in a daily dose once daily in the evening, before bedtime. It usually takes 6-24 months for stones to dissolve. If after 12 months of treatment the size of the stones does not decrease, then treatment should be stopped.

The effectiveness of treatment should be assessed every 6 months with ultrasound or radiography. During the interim examination, it is necessary to assess whether calcification of the stones has occurred during the intervening period. In case of calcification of stones, treatment should be discontinued.

Primary biliary cirrhosis:

The daily dose depends on body weight and ranges from 2 to 6 capsules (approximately 10 to 15 mg of ursodeoxycholic acid per 1 kg of body weight).

In the first 3 months of treatment, the drug should be divided into several doses throughout the day. After improving liver parameters, the daily dose of the drug can be taken once, in the evening. The following mode of application is recommended:

Capsules should be taken regularly, without chewing, with a small amount of water.

The use of Phosphogliv® URSO for the treatment of primary biliary cirrhosis can be continued indefinitely.

In patients with primary biliary cirrhosis, in rare cases, clinical symptoms may worsen at the beginning of treatment, for example, itching may become more frequent. In this case, treatment should be continued, taking one capsule daily, then the dosage should be gradually increased (increasing the daily dose by one capsule weekly) until the recommended dosage regimen is achieved again.

Primary sclerosing cholangitis:

Daily dose 12-15 mg/kg; if necessary, the dose can be increased to 20 mg/kg in 2-3 doses. The duration of therapy ranges from 6 months to several years.

Reviews

Patients who have already used the medicine leave positive reviews and confirm its effectiveness. After taking it, the condition of the liver noticeably improves, and troubling problems disappear. The drug allows you to eliminate the signs of the disease, and your overall health and test results noticeably improve. The same reviews are left by patients with more severe pathologies, such as hepatitis C. After use, there is also a noticeable improvement in the condition of the skin.

Another undeniable advantage is the reasonable price.

Doctors also speak positively about the drug. They prescribe it for the treatment of liver diseases of various origins.

Phosphogliv

Phosphogliv is a domestic hepatoprotector, which is a combination of phospholipids (phosphatidylcholine) and glycyrrhizic acid. In addition to the hepatoprotective properties, the drug has a membrane-stabilizing and antiviral effect. Used in the treatment of viral hepatitis, hepatosis and other liver lesions, as well as skin diseases (psoriasis, eczema, etc.).

Chronic viral hepatitis is a pressing problem, both on a Russian and global scale. Vaccination can prevent acute hepatitis, but in the fight against chronic forms of this disease, it is, unfortunately, not so effective. Classic drug therapy for chronic hepatitis is a rather complex and expensive undertaking, motivating pharmacologists to create new, more effective drugs. One of these promising drugs is the drug phosphogliv, which, according to its creators, has no analogues on the global pharmaceutical market and is an absolute pioneer in many aspects. Thus, this is the only hepatoprotector that has both etiotropic and pathogenetic effects. The uniqueness of phosphogliv also lies in the combination of hepatoprotective and antiviral effects under the “roof” of one dosage form. One of the components of this drug, phosphatidylcholine, is endowed with the ability to structurally restore liver cells, acting like a “membrane sealant” that patches up holes in biological membranes. This pharmacologically active “ingredient” of phosphogliv is its main active principle, normalizing the metabolism of proteins and lipids and preventing the loss of enzymes by liver cells, restoring the detoxifying function of this organ. Phosphatidylcholine suppresses the excessive formation of connective tissue, which reduces the risk of developing hepatic fibrosis and cirrhosis, as well as improving the prognosis and increasing the quality of life of patients.

Another component of the drug is glycyrrhizic acid, a substance with antiviral activity that inhibits the reproduction of viruses in the body by activating the synthesis of interferons, stimulating the formation of phagocytes and the activity of natural killer cells. Being an antioxidant and exhibiting a membrane-stabilizing effect, glycyrrhizic acid potentiates the hepatoprotective effect of phospholipids and has anti-allergic and anti-inflammatory effects. The novelty of phosphogliv also lies in the unparalleled technology for creating a dry powder form of granular soy phospholipids. This made it possible to increase the shelf life of the capsulated dosage form. The original technology for producing a lyophilisate for intravenous administration made it possible to create a stable phospholipid nanosystem consisting of emulsified micelles and liposomes and free of toxic detergents (surfactants). Complex micelles can be stored in an active state for several years, which is of great clinical importance, because the patient in this case receives the active drug, and not the product of metabolic processes of pharmacologically active substances.

Phosphogliv has undergone a number of tests in leading Russian clinics. Its effect was assessed according to many criteria, including improvement in the patient’s general condition, elimination of symptoms of intoxication, disappearance of the yellow color of the skin, the presence/absence of bile in the stool, a decrease in the concentration of bilirubin and the activity of liver enzymes. As a result, all patients receiving phosphogliv showed positive dynamics. Thus, this drug has been demonstrated to be highly effective in treating liver diseases. It significantly improves the synthetic function of this organ and reduces the manifestations of liver failure. The drug is well tolerated and has a favorable safety profile.